| pubmed-article:1489885 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1489885 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:1489885 | lifeskim:mentions | umls-concept:C0042449 | lld:lifeskim |
| pubmed-article:1489885 | lifeskim:mentions | umls-concept:C0332835 | lld:lifeskim |
| pubmed-article:1489885 | lifeskim:mentions | umls-concept:C0011145 | lld:lifeskim |
| pubmed-article:1489885 | lifeskim:mentions | umls-concept:C0020507 | lld:lifeskim |
| pubmed-article:1489885 | lifeskim:mentions | umls-concept:C0024706 | lld:lifeskim |
| pubmed-article:1489885 | lifeskim:mentions | umls-concept:C0301630 | lld:lifeskim |
| pubmed-article:1489885 | lifeskim:mentions | umls-concept:C2348480 | lld:lifeskim |
| pubmed-article:1489885 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:1489885 | pubmed:dateCreated | 1993-3-2 | lld:pubmed |
| pubmed-article:1489885 | pubmed:abstractText | Reversed vein grafting exposes the venous tissue to a period of ischemia, reperfusion and subsequent free radical generation which may contribute to endothelial injury and/or damage, smooth muscle cell proliferation and the later development of intimal hyperplasia. The effects of ex vivo treatment with desferrioxamine Mn+3 (DFMn), a cell-permeable free radical scavenger, on the development of intimal hyperplasia in experimental vein grafts was examined. Twenty New Zealand white rabbits received a reversed vein interposition bypass graft into the ipsilateral common carotid artery. Ten explanted veins were immersed in a heparinized (5 IU/ml) saline solution, and 10 others were immersed in a similar solution containing DFMn (1 mM) for 45 min prior to reimplantation. There were no short-term functional or morphologic toxic side effects associated with DFMn treatment on either the endothelial or smooth muscle cells of the veins. At 28 days, grafts (n = 20) were perfusion-fixed in vivo for histological and morphometric studies. There was a significant reduction in intimal thickening in the DFMn-treated group compared to the untreated group. The thicknesses of the intimal hyperplasia in the proximal segments were 50.6 +/- 6.3 vs. 76.9 +/- 3.2 microns (p < 0.05), in the middle segments 42.0 +/- 5.0 vs. 84.3 +/- 5.4 microns (p < 0.05) and in the distal segments 55.7 +/- 5.0 vs. 88.3 +/- 6.2 microns (p < 0.05) for treated and untreated animals, respectively. No evidence of long-term toxicity was found.(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:1489885 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1489885 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1489885 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1489885 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1489885 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1489885 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1489885 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1489885 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1489885 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1489885 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1489885 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1489885 | pubmed:issn | 1018-1172 | lld:pubmed |
| pubmed-article:1489885 | pubmed:author | pubmed-author:MurrayJ JJJ | lld:pubmed |
| pubmed-article:1489885 | pubmed:author | pubmed-author:DaviesM GMG | lld:pubmed |
| pubmed-article:1489885 | pubmed:author | pubmed-author:HagenP OPO | lld:pubmed |
| pubmed-article:1489885 | pubmed:author | pubmed-author:SchumanR WRW | lld:pubmed |
| pubmed-article:1489885 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1489885 | pubmed:volume | 29 | lld:pubmed |
| pubmed-article:1489885 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1489885 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1489885 | pubmed:pagination | 405-9 | lld:pubmed |
| pubmed-article:1489885 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:1489885 | pubmed:meshHeading | pubmed-meshheading:1489885-... | lld:pubmed |
| pubmed-article:1489885 | pubmed:meshHeading | pubmed-meshheading:1489885-... | lld:pubmed |
| pubmed-article:1489885 | pubmed:meshHeading | pubmed-meshheading:1489885-... | lld:pubmed |
| pubmed-article:1489885 | pubmed:meshHeading | pubmed-meshheading:1489885-... | lld:pubmed |
| pubmed-article:1489885 | pubmed:meshHeading | pubmed-meshheading:1489885-... | lld:pubmed |
| pubmed-article:1489885 | pubmed:meshHeading | pubmed-meshheading:1489885-... | lld:pubmed |
| pubmed-article:1489885 | pubmed:meshHeading | pubmed-meshheading:1489885-... | lld:pubmed |
| pubmed-article:1489885 | pubmed:meshHeading | pubmed-meshheading:1489885-... | lld:pubmed |
| pubmed-article:1489885 | pubmed:meshHeading | pubmed-meshheading:1489885-... | lld:pubmed |
| pubmed-article:1489885 | pubmed:meshHeading | pubmed-meshheading:1489885-... | lld:pubmed |
| pubmed-article:1489885 | pubmed:meshHeading | pubmed-meshheading:1489885-... | lld:pubmed |
| pubmed-article:1489885 | pubmed:meshHeading | pubmed-meshheading:1489885-... | lld:pubmed |
| pubmed-article:1489885 | pubmed:articleTitle | Reduction of vein graft intimal hyperplasia by ex vivo treatment with desferrioxamine manganese. | lld:pubmed |
| pubmed-article:1489885 | pubmed:affiliation | Department of Surgery, Duke University Medical Center, Durham, N.C. 27710. | lld:pubmed |
| pubmed-article:1489885 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1489885 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:1489885 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:1489885 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1489885 | lld:pubmed |
